Idogen AB Interim report January–September 2019
”With new strong patents being prepared, a solid scientific foundation and an organisation that has demonstrated high levels of competence, flexibility and efficiency, Idogen is now ready to take its tolerogenic cell therapies to clinical trials.”
Anders Karlsson, CEOTHIRD QUATER (JULY – SEPTEMBER 2019)
· Other operating income amounted to KSEK 973 (0). · Operating loss amounted to KSEK -6,753 (-7,268). · Loss for the period amounted to KSEK -6,622 (-7,318). · Cash flow from operating activities was KSEK -8,624 (-6,860). · Loss per share before dilution was SEK -0.